Synthesis and pharmacokinetics of a novel macromolecular prodrug of Tacrolimus (FK506), FK506-dextran conjugate.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Journal of Controlled Release

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0168-3659(98)00150-3PMID 10084872
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Abnormal differentiation of thymocytes induced by free cyclosporine is avoided when cyclosporine bound to N-(2-hydroxypropyl)methacrylamide copolymer carrier is used.

  1997cited by this paper
• A randomized trial comparing safety and efficacy of OKT3 and a monoclonal anti-interleukin-2 receptor antibody (BT563) in the prevention of acute rejection after heart transplantation.

  1996cited by this paper
• alpha/beta-T cell receptor-directed therapy in rat allograft recipients. Long-term survival of cardiac allografts after pretreatment with R73 mAb is associated with upregulation of Th2-type cytokines.

  1996cited by this paper
• FK506 nephrotoxicity: morphologic and physiologic characterization of a rat model.

  1995cited by this paper
• Physicochemical, Pharmacokinetic and Pharmacodynamic Evaluation of Liposomal Tacrolimus (FK 506) in Rats

  1995cited by this paper
• Macromolecular drug carrier systems in cancer chemotherapy: macromolecular prodrugs.

  1995cited by this paper
• Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes.

  1994cited by this paper
• Physiological Parameters in Laboratory Animals and Humans

  1993cited by this paper
• Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat.

  1992cited by this paper
• Preparation and properties of the immunoconjugate composed of anti-human colon cancer monoclonal antibody and mitomycin C-dextran conjugate.

  1992cited by this paper
• FK506‐INDUCED KIDNEY TUBULAR CELL INJURY

  1992cited by this paper
• Tumor Localization and in vivo Antitumor Activity of the Immunoconjugate Composed of Anti‐human Colon Cancer Monoclonal Antibody and Mitomycin C‐Dextran Conjugate

  1991cited by this paper
• Pharmacokinetic study of FK 506 in the rat.

  1991cited by this paper
• Pharmacokinetics of FK 506: preclinical and clinical studies.

  1990cited by this paper
• Disposition Characteristics of Macromolecules in Tumor-Bearing Mice

  1990cited by this paper
• Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. II. Inhibition of the production of IL-2 and gamma-IFN, but not B cell-stimulating factor 2.

  1989cited by this paper
• EFFECT OF A NEW IMMUNOSUPPRESSIVE AGENT, FK506, ON HUMAN LYMPHOCYTE RESPONSES IN VITRO: I. Inhibition of Expression of Alloanticen‐Activated Suppressor Cells, As Well As Induction of Alloreactivity

  1989cited by this paper
• Soluble macromolecular carriers for the delivery of antitumour drugs

  1989cited by this paper
• Disposition and Tumor Localization of Mitomycin C–Dextran Conjugates in Mice

  1987cited by this paper
• Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A.

  1987cited by this paper
• Development of a novel polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate with anionic charge. II. Disposition and pharmacokinetics following intravenous and intramuscular administration

  1987cited by this paper
• Development of a novel polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate with anionic charge. I. Physicochemical characteristics and in vivo and in vitro antitumor activities

  1987cited by this paper
• Effect of FK-506 on human mixed lymphocyte reaction in vitro.

  1987cited by this paper
• Macromolecular prodrugs I. Kinetics and mechanism of hydrolysis of O-benzoyl dextran conjugates in aqueous buffer and in human plasma

  1985cited by this paper
• Macromolecule-drug conjugates in targeted cancer chemotherapy.

  1984cited by this paper
• Enhanced lymphatic delivery of mitomycin C conjugated with dextran.

  1984cited by this paper
• A pharmacokinetic analysis program (multi) for microcomputer.

  1981cited by this paper
• Mitomycin C‐dextran conjugate: a novel high molecular weight pro‐drug of mitomycin C

  1980cited by this paper
• Determination of free amino groups in proteins by trinitrobenzenesulfonic acid.

  1966cited by this paper
• Quantitative Relations in the Physiological Constitutions of Mammals.

  1949cited by this paper

• Stimuli-Responsive Polymeric Conjugates of Tacrolimus: A pH/Redox-Triggered Approach toward Precision Drug Delivery.

  2025cites this paper
• Redox-Responsive Hyaluronic Acid-Tacrolimus Conjugate: Synthesis, Characterization, and In Vitro Immunosuppressive Activity.

  2023cites this paper
• Biopolymer–drug conjugates as biomaterials

  2021cites this paper
• Engineering L-tyrosine based polycarbonate copolymers as degradable devices for long-term, localized delivery of hydrophobic macrolide immunosuppressants to prevent transplant rejection

  2021cites this paper
• Distinct effects of calcineurin dependent and independent immunosuppressants on endotoxaemia‐induced nephrotoxicity in rats: Role of androgens

  2021cites this paper
• Topical tacrolimus νanocapsules eye drops for therapeutic effect enhancement in both anterior and posterior ocular inflammation models.

  2021cites this paper
• Sustained A1 Adenosine Receptor Antagonist Drug Release from Nanoparticles Functionalized by a Neural Tracing Protein.

  2021cites this paper
• Head-to-head comparative pharmacokinetic and biodistribution (PK/BD) study of two dexamethasone Prodrug Nanomedicines on lupus-prone NZB/WF1 mice.

  2020cites this paper
• Solid dispersion-based pellet for colon delivery of tacrolimus through time- and pH-dependent layer coating: preparation, in vitro and in vivo studies

  2019cites this paper
• A perspective on magnetic core–shell carriers for responsive and targeted drug delivery systems

  2019cites this paper
• Diaphragmatic recovery in rats with cervical spinal cord injury induced by a theophylline nanoconjugate: Challenges for clinical use

  2019cites this paper
• Nanoparticle Synthesis for Glucose-Loaded Mesoporous Silica and Sucrose Hydrolysis Strategies for Bioanalyte Detection Applications using a Personal Glucose Meter

  2019cites this paper
• Hyaluronic Acid-Tacrolimus Bioconjugate: Synthesis, Characterization, and Pharmacokinetic Investigation of an Acid-Responsive Macromolecular Prodrug.

  2019cites this paper
• Tacrolimus: An updated review on delivering strategies for multifarious diseases

  2018cites this paper
• Linkers: The key elements for the creation of efficient nanotherapeutics

  2018cites this paper
• Preclinical characterization and clinical evaluation of tacrolimus eye drops

  2018cites this paper
• A review of drug release mechanisms from nanocarrier systems.

  2017cites this paper
• Tacrolimus Ointment for Refractory Posterior Blepharitis

  2017cites this paper
• Polysaccharide-based materials in macromolecular prodrug design and development

  2017cites this paper
• Design, Characterization, and In Vivo Pharmacokinetics of Tacrolimus Proliposomes

  2016cites this paper
• Therapeutic effect of 0.1% Tacrolimus Eye Ointment in Allergic Ocular Diseases.

  2016cites this paper
• Anticorps contre la protéine accessoire du récepteur humain de l'interleukine 1 (il1 rap) et leurs utilisations

  2015cites this paper
• Synthesis and Characterizations of Silver Colloid Nanoparticles Stabilized by Dextran

  2015cites this paper
• Bovine serum albumin nanoparticles for delivery of tacrolimus to reduce its kidney uptake and functional nephrotoxicity.

  2015cites this paper
• Mechanisms of drug release in nanotherapeutic delivery systems.

  2015cites this paper
• Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement

  2014cites this paper
• Treatment of cerebral ischemia‐reperfusion injury with PEGylated liposomes encapsulating FK506

  2013cites this paper
• Pterygium Masking Bifid Medial Rectus Insertion and Strabismic Amblyopia

  2013cites this paper
• Tacrolimus for Ophthalmic Use: An Update

  2013cites this paper
• Preparation of silver core nanoparticles with polysaccharide shell

  2012cites this paper
• Mechanisms of Calcineurin Inhibitor Nephrotoxicity in Chronic Allograft Injury

  2012cites this paper
• Formulation strategies for drug delivery of tacrolimus: An overview

  2012cites this paper
• Modified polysaccharides as versatile materials in controlled delivery of antidegenerative agents.

  2012cites this paper
• Immunophilin-loaded erythrocytes as a new delivery strategy for immunosuppressive drugs.

  2011cites this paper
• Tacrolimus in the Treatment of Ocular Diseases

  2011cites this paper
• Rational design and development of colon-specific prodrugs.

  2011cites this paper
• Exploring a "Nature-Inspired" Strategy for Enhancing the Pharmacology of Small Molecules: Towards the Development of Next Generation Anti-Infectives.

  2011cites this paper
• Otrzymywanie nanocząstek srebra pokrywanych polialdehydo-dekstranem

  2011cites this paper
• Chemistry of the immunomodulatory macrolide ascomycin and related analogues.

  2011cites this paper
• Polysaccharide-Based Anticancer Prodrugs

  2010cites this paper
• Preparation of 0.05% FK506 Suspension Eyedrops and Its Pharmacokinetics After Topical Ocular Administration

  2009cites this paper
• Biodegradable Polymers for Drug Delivery Systems

  2009cites this paper
• FK506-binding protein (FKBP) partitions a modified HIV protease inhibitor into blood cells and prolongs its lifetime in vivo

  2009cites this paper
• Synthesis of dextran‐metaxalone conjugates and study on their control drug release behaviors

  2008cites this paper
• Preliminary Study of the Effect of FK506 Nanospheric-Suspension Eye Drops on Rejection of Penetrating Keratoplasty

  2008cites this paper
• UNIVERSITY OF FLORIDA THESIS OR DISSERTATION FORMATTING TEMPLATE

  2008cites this paper
• Macromolecular Prodrugs of Small Molecules

  2007cites this paper
• Attenuation of Acute Rejection in a Rat Liver Transplantation Model by a Liver-Targeted Dextran Prodrug of Methylprednisolone

  2006cites this paper
• The protein-binding and drug release properties of macromolecular conjugates containing daptomycin and dextran.

  2006cites this paper
• Polymer-drug conjugates: Progress in polymeric prodrugs

  2006cites this paper
• Advances in prodrug design.

  2005cites this paper
• Latenciação e formas avançadas de transporte de fármacos

  2005cites this paper
• Biodegradable Microsphere‐Loaded Tacrolimus Enhanced the Effect on Mice Islet Allograft and Reduced the Adverse Effect on Insulin Secretion

  2004cites this paper
• Dextran-Methylprednisolone Succinate as a Prodrug of Methylprednisolone: Local Immunosuppressive Effects in Liver After Systemic Administration to Rats

  2003influential citation
• Mechanisms of Clinically Relevant Drug Interactions Associated with Tacrolimus

  2002cites this paper
• Effect of Chemical Modification on the Pharmacokinetics and Biodistribution of Carboxymethyl Dextran as a Drug Carrier

  2002cites this paper
• Dextran-methylprednisolone succinate as a prodrug of methylprednisolone: plasma and tissue disposition.

  2001cites this paper
• Dextran-Methylprednisolone Succinate as a Prodrug of Methylprednisolone: Immunosuppressive Effects After In Vivo Administration to Rats

  2000influential citation
• Dextran-methylprednisolone succinate as a prodrug of methylprednisolone: in vitro immunosuppressive effects on rat blood and spleen lymphocytes.

  2000cites this paper
• PCL-b-PEO micelles as a delivery vehicle for FK506: assessment of a functional recovery of crushed peripheral nerve.

  2000cites this paper
• PCL-b-PEO Micelles as a Delivery Vehicle for FK506: Assessment of a Functional Recovery of Crushed Peripheral Nerve

  2000influential citation
• Dextrans for targeted and sustained delivery of therapeutic and imaging agents.

  2000cites this paper